{"title":"血小板糖蛋白VI受体拮抗剂及其神经保护活性的发现:计算机、体外和体内研究。","authors":"Mohammad Aquib Siddiqui, Poorvi Saraf, Sushant Kumar Shrivastava, Sudha Madhavi Penumaka, Debabrata Mandal, Ravi Saini, Abhishek Pathak, Kakarla Ramakrishna, Sairam Krishnamurthy","doi":"10.1007/s13205-025-04530-z","DOIUrl":null,"url":null,"abstract":"<p><p>The present study utilized a drug repurposing approach to identify potential GPVI receptor antagonists among FDA-approved drugs. Computational and molecular dynamics simulations revealed that adapalene and ranolazine exhibit strong binding affinities to GPVI receptors and stabilize GPVI proteins, respectively. Both compounds inhibited collagen-induced platelet aggregation, evidenced by the suppression of Syk tyrosine kinase expression, a marker of platelet activation, via GPVI stimulation, as confirmed through flow cytometry analysis. Further analysis using circular dichroism and Raman spectroscopy indicated that collagen exposure induced conformational changes in the α-helical domains of platelets, which were stabilized upon treatment with adapalene and ranolazine. Moreover, thrombotic events can lead to cerebral cell death due to hypoxia, which may be mitigated by neuroprotective compounds. Adapalene and ranolazine were assessed for their neuroprotective capabilities. The results showed that these compounds exhibited neuroprotective effects in SHSY5Y neuroblastoma cells subjected to oxygen-glucose deprivation/reperfusion (OGD/R) injury, reducing HIF-1α expression, ROS production, lipid peroxidation, and caspase-3 levels, while also improving mitochondrial membrane potential and glutathione levels. Acridine orange and propidium iodide staining studies further confirmed a decrease in apoptosis. In the FeCl<sub>3</sub>-induced carotid artery thrombosis model, ranolazine effectively inhibited platelet aggregation by modulating GPVI receptor activity, reducing intracellular calcium levels, and enhancing cAMP signaling. It also suppressed critical platelet activation mediators, including COX-1, TXB<sub>2</sub>, and PGE<sub>2</sub>, thereby mitigating thrombus formation. Collectively, these results suggest that adapalene and ranolazine may serve as multimodal therapeutic agents with the potential to treat both thrombotic and neurological diseases. Future studies focusing on the adapalene and ranolazine molecular mechanisms, bleeding risk, dose titration, and long-term safety while managing thrombotic disorders have to be investigated.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13205-025-04530-z.</p>","PeriodicalId":7067,"journal":{"name":"3 Biotech","volume":"15 10","pages":"357"},"PeriodicalIF":2.9000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12450859/pdf/","citationCount":"0","resultStr":"{\"title\":\"Discovery of platelet glycoprotein VI receptor antagonists and their neuroprotective activity: an in silico, in vitro, and in vivo study.\",\"authors\":\"Mohammad Aquib Siddiqui, Poorvi Saraf, Sushant Kumar Shrivastava, Sudha Madhavi Penumaka, Debabrata Mandal, Ravi Saini, Abhishek Pathak, Kakarla Ramakrishna, Sairam Krishnamurthy\",\"doi\":\"10.1007/s13205-025-04530-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The present study utilized a drug repurposing approach to identify potential GPVI receptor antagonists among FDA-approved drugs. Computational and molecular dynamics simulations revealed that adapalene and ranolazine exhibit strong binding affinities to GPVI receptors and stabilize GPVI proteins, respectively. Both compounds inhibited collagen-induced platelet aggregation, evidenced by the suppression of Syk tyrosine kinase expression, a marker of platelet activation, via GPVI stimulation, as confirmed through flow cytometry analysis. Further analysis using circular dichroism and Raman spectroscopy indicated that collagen exposure induced conformational changes in the α-helical domains of platelets, which were stabilized upon treatment with adapalene and ranolazine. Moreover, thrombotic events can lead to cerebral cell death due to hypoxia, which may be mitigated by neuroprotective compounds. Adapalene and ranolazine were assessed for their neuroprotective capabilities. The results showed that these compounds exhibited neuroprotective effects in SHSY5Y neuroblastoma cells subjected to oxygen-glucose deprivation/reperfusion (OGD/R) injury, reducing HIF-1α expression, ROS production, lipid peroxidation, and caspase-3 levels, while also improving mitochondrial membrane potential and glutathione levels. Acridine orange and propidium iodide staining studies further confirmed a decrease in apoptosis. In the FeCl<sub>3</sub>-induced carotid artery thrombosis model, ranolazine effectively inhibited platelet aggregation by modulating GPVI receptor activity, reducing intracellular calcium levels, and enhancing cAMP signaling. It also suppressed critical platelet activation mediators, including COX-1, TXB<sub>2</sub>, and PGE<sub>2</sub>, thereby mitigating thrombus formation. Collectively, these results suggest that adapalene and ranolazine may serve as multimodal therapeutic agents with the potential to treat both thrombotic and neurological diseases. Future studies focusing on the adapalene and ranolazine molecular mechanisms, bleeding risk, dose titration, and long-term safety while managing thrombotic disorders have to be investigated.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13205-025-04530-z.</p>\",\"PeriodicalId\":7067,\"journal\":{\"name\":\"3 Biotech\",\"volume\":\"15 10\",\"pages\":\"357\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12450859/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"3 Biotech\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.1007/s13205-025-04530-z\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/9/21 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"3 Biotech","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1007/s13205-025-04530-z","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/21 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
Discovery of platelet glycoprotein VI receptor antagonists and their neuroprotective activity: an in silico, in vitro, and in vivo study.
The present study utilized a drug repurposing approach to identify potential GPVI receptor antagonists among FDA-approved drugs. Computational and molecular dynamics simulations revealed that adapalene and ranolazine exhibit strong binding affinities to GPVI receptors and stabilize GPVI proteins, respectively. Both compounds inhibited collagen-induced platelet aggregation, evidenced by the suppression of Syk tyrosine kinase expression, a marker of platelet activation, via GPVI stimulation, as confirmed through flow cytometry analysis. Further analysis using circular dichroism and Raman spectroscopy indicated that collagen exposure induced conformational changes in the α-helical domains of platelets, which were stabilized upon treatment with adapalene and ranolazine. Moreover, thrombotic events can lead to cerebral cell death due to hypoxia, which may be mitigated by neuroprotective compounds. Adapalene and ranolazine were assessed for their neuroprotective capabilities. The results showed that these compounds exhibited neuroprotective effects in SHSY5Y neuroblastoma cells subjected to oxygen-glucose deprivation/reperfusion (OGD/R) injury, reducing HIF-1α expression, ROS production, lipid peroxidation, and caspase-3 levels, while also improving mitochondrial membrane potential and glutathione levels. Acridine orange and propidium iodide staining studies further confirmed a decrease in apoptosis. In the FeCl3-induced carotid artery thrombosis model, ranolazine effectively inhibited platelet aggregation by modulating GPVI receptor activity, reducing intracellular calcium levels, and enhancing cAMP signaling. It also suppressed critical platelet activation mediators, including COX-1, TXB2, and PGE2, thereby mitigating thrombus formation. Collectively, these results suggest that adapalene and ranolazine may serve as multimodal therapeutic agents with the potential to treat both thrombotic and neurological diseases. Future studies focusing on the adapalene and ranolazine molecular mechanisms, bleeding risk, dose titration, and long-term safety while managing thrombotic disorders have to be investigated.
Supplementary information: The online version contains supplementary material available at 10.1007/s13205-025-04530-z.
3 BiotechAgricultural and Biological Sciences-Agricultural and Biological Sciences (miscellaneous)
CiteScore
6.00
自引率
0.00%
发文量
314
期刊介绍:
3 Biotech publishes the results of the latest research related to the study and application of biotechnology to:
- Medicine and Biomedical Sciences
- Agriculture
- The Environment
The focus on these three technology sectors recognizes that complete Biotechnology applications often require a combination of techniques. 3 Biotech not only presents the latest developments in biotechnology but also addresses the problems and benefits of integrating a variety of techniques for a particular application. 3 Biotech will appeal to scientists and engineers in both academia and industry focused on the safe and efficient application of Biotechnology to Medicine, Agriculture and the Environment.